Atrium Therapeutics, Inc. (RNA) 是一家上市公司 屬於 醫療保健 板塊，經營於 生物科技 產業. 公司總部位於 San Diego, CA, 美国. 現任CEO為 Kathleen Gallagher.
RNA 擁有 IPO日期為 2026-02-27, 在 NASDAQ Global Select, 市值為 $225.59M.
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
